341 related articles for article (PubMed ID: 33609962)
21. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
22. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
[TBL] [Abstract][Full Text] [Related]
23. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
[TBL] [Abstract][Full Text] [Related]
24. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Migdalska-Richards A; Daly L; Bezard E; Schapira AH
Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541
[TBL] [Abstract][Full Text] [Related]
25. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Ron I; Rapaport D; Horowitz M
Hum Mol Genet; 2010 Oct; 19(19):3771-81. PubMed ID: 20643691
[TBL] [Abstract][Full Text] [Related]
26. Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.
Ivanova MM; Changsila E; Turgut A; Goker-Alpan O
Am J Transl Res; 2018; 10(11):3750-3761. PubMed ID: 30662625
[TBL] [Abstract][Full Text] [Related]
27. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells.
Deen MC; Zhu Y; Gros C; Na N; Gilormini PA; Shen DL; Bhosale S; Anastasi N; Wang R; Shan X; Harde E; Jagasia R; Lynn FC; Vocadlo DJ
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2200553119. PubMed ID: 35858317
[TBL] [Abstract][Full Text] [Related]
28. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
Babajani G; Tropak MB; Mahuran DJ; Kermode AR
Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
[TBL] [Abstract][Full Text] [Related]
30. High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified.
Huang Y; Jia X; Tang C; Liu S; Sheng H; Zhao X; Zeng C; Liu L
Clin Chim Acta; 2020 Jul; 506():22-27. PubMed ID: 32165122
[TBL] [Abstract][Full Text] [Related]
31. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV
Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625
[TBL] [Abstract][Full Text] [Related]
32. Structural and dynamics insights into the GBA variants associated with Parkinson's disease.
Mahmood A; Samad A; Bano S; Umair M; Ajmal A; Ilyas I; Shah AA; Li P; Hu J
J Biomol Struct Dyn; 2024 Aug; 42(12):6256-6268. PubMed ID: 37434319
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage.
Cleeter MW; Chau KY; Gluck C; Mehta A; Hughes DA; Duchen M; Wood NW; Hardy J; Mark Cooper J; Schapira AH
Neurochem Int; 2013 Jan; 62(1):1-7. PubMed ID: 23099359
[TBL] [Abstract][Full Text] [Related]
34. Neurological effects of glucocerebrosidase gene mutations.
Mullin S; Hughes D; Mehta A; Schapira AHV
Eur J Neurol; 2019 Mar; 26(3):388-e29. PubMed ID: 30315684
[TBL] [Abstract][Full Text] [Related]
35. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
36. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
Trapero A; Alfonso I; Butters TD; Llebaria A
J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
[TBL] [Abstract][Full Text] [Related]
37. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
38. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
Vieira SRL; Schapira AHV
Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
[TBL] [Abstract][Full Text] [Related]
39. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.
Magalhaes J; Gegg ME; Migdalska-Richards A; Schapira AH
Sci Rep; 2018 Jan; 8(1):1385. PubMed ID: 29362387
[TBL] [Abstract][Full Text] [Related]
40. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
Shanmuganathan M; Britz-McKibbin P
Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
